Open AccessPrognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group
Author(s) -
David A. Rodeberg,
Julie A. Stoner,
Andrea HayesJordan,
Simon C. Kao,
Suzanne L. Wolden,
Steve Qualman,
William H. Meyer,
Douglas S. Hawkins
Publication year - 2009
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2008.19.5933
Subject(s) - medicine , rhabdomyosarcoma , hazard ratio , progressive disease , adjuvant therapy , minimal residual disease , surgery , oncology , gastroenterology , disease , confidence interval , sarcoma , chemotherapy , pathology , leukemia
Some patients with rhabdomyosarcoma (RMS) achieve less than a complete response (CR) despite receiving all planned therapy. We assessed the impact of best response at the completion of all therapy on patient outcome.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom